Ex-vivo expanded cytotoxic autologous AML-reactive T cell threrapy (University of California, San Diego)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEx-vivo expanded cytotoxic autologous AML-reactive T cell threrapy (University of California, San Diego)

Drug Alias NameCytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC)体外扩增的细胞毒性自体AML反应性T细胞（CTL）疗法AMLCTLAML_CTL cells

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionUpdating

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California San Diego

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of California San Diego

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A